Compare ADMA Biologics Inc (ADMA) vs Ross Stores, Inc. (ROST) Price & Performance

ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.

Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.

Ross Stores (ROST) trades at $255.23, up 0.36% on the day, near its consensus price target of $259. The stock shows strong momentum with a bullish technical signal and consistent earnings beats, including Q1 2026 EPS of $2.02 versus $1.73 expected. Revenue growth accelerated to $21.13B in 2025, with net income margin improving to 9.74%. Recent expansion includes 47 new stores opened in June-July 2026, supporting future growth.

Outlook remains positive given robust fundamentals and analyst optimism, but valuation multiples like P/E of 35.65 suggest premium pricing. Key risks include consumer spending sensitivity and competitive pressures in discount retail. The stock offers growth potential with disciplined execution, though investors should weigh high valuation against earnings sustainability.